International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes

Peter L. Greenberg, Christopher Cox, Michelle M. LeBeau, +12

Blood

Proposals for the classification of the myelodysplastic syndromes

John M. Bennett, Daniel Catovsky, MT Daniel, +4

British Journal of Haematology

Hematological MalignancyHematologyDiagnosisPathologyHistopathology +4

Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

Seema Singhal, Jayesh Mehta, Raman Desikan, +11

New England Journal of Medicine

Thalidomide is an inhibitor of angiogenesis.

Robert J. D’Amato, Michael Loughnan, Evelyn Flynn, +1

Proceedings of the National Academy of Sciences

AngiogenesisDevelopmental BiologyOphthalmologyVascular PharmacologyPharmacology +11

Report of an international working group to standardize response criteria for myelodysplastic syndromes.

Bruce D. Cheson, John M. Bennett, Hagop M. Kantarjian, +12

PubMed

Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes

Álvaro Aguayo, Hagop M. Kantarjian, Taghi Manshouri, +9

Blood

Thalidomide Costimulates Primary Human T Lymphocytes, Preferentially Inducing Proliferation, Cytokine Production, and Cytotoxic Responses in the CD8+ Subset

Patrick Haslett, Laura G. Corral, Matthew L. Albert, +1

The Journal of Experimental Medicine

Inhibition of Angiogenesis by Thalidomide Requires Metabolic Activation, Which Is Species-dependent

Kenneth S. Bauer, Shannon C. Dixon, William D. Figg

Biochemical Pharmacology

AngiogenesisMedicinePhysiologyVascular BiologyMetabolic Remodeling +3

Angiogenesis in myelodysplastic syndromes

Giancarlo Pruneri, Francesco Bertolini, Davide Soligo, +6

British Journal of Cancer

The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures

Sheena McHugh, Ian R. Rifkin, John Deighton, +4

Clinical & Experimental Immunology